ANI Pharmaceuticals (ANIP) provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences (ALIM). ANI said in a statement: “We note the Alimera press release issued today. The Company continues to work in good faith toward closing of the acquisition. Any delay is a result of discussions regarding closing conditions, which the Company expects to resolve promptly.” Alimera Sciences, this morning announced that it has filed a lawsuit in the Delaware Court of Chancery to compel ANI “to fulfill its contractual obligation to close the transaction.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Announces Debt Clearance and Notes Sale
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering
- ANI Pharmaceuticals announces proposed convertible senior notes offering
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering